David R. Spriggs, MD
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improved relapse-free survival (RFS) and overall survival (OS) for women with newly diagnosed stage III epithelial ovarian cancer.
“Primary cytoreductive surgery for certain patients with ovarian cancer remains the preferred approach over neoadjuvant treatment, and administration of HIPEC at the time of interval cytoreductive surgery does not change that,” they wrote. “New confirmatory clinical investigations of HIPEC are needed to clarify some of the unanswered questions before HIPEC can become a common treatment strategy. These considerations will be important for clinical trial investigators as they focus on the positive effect of HIPEC as an intervention as compared with the effects of promising new agent combinations or immunotherapy treatments.”
- van Driel W, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018; 378:230-240.
- Spriggs DR, Zivanovic O. Ovarian cancer treatment—Are we getting warmer? N Engl J Med. 2018; 378:293-294.
... to read the full story